Given the need for improved efficiency and quicker time-to-market, IT outsourcing landscape of life sciences companies is set to change. Many firms are already experimenting with a combination of in-housing and outsourcing constructs. However, the broad benefits of such models are yet to be observed.
In this Everest Group viewpoint, we discuss how the outsourcing engagements could alter with the changing business dynamics. We analyze various aspects from the lens of enterprises and service providers. Further, we also take a deep dive into understanding various intricacies with the new model of AstraZeneca and Novartis. We also examine how service providers are equipping themselves to ward off any adverse impact caused by the change in the enterprises’ sourcing models.
Note: this report is from 2012. See our most recent R2R research report.
The Finance & Accounting (F&A) function comprises three end-to-end processes – Procure-to-Pay (P2P), Order-to-Cash (O2C), and Record-to-Report (R2R). This report focuses on…
